Loading clinical trials...

Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma | Clinical Trials | Clareo Health

UNKNOWNNA

Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

NCT04717999•UWELL Biopharma

Summary

This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma

Eligibility

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse.
•Hemoglobin ≥ 9.0 g/dl, absolute neutrophil count (ANC) ≥ 1,000 cells/µl, platelets ≥ 125,000 cells/µl
•No active infection of HIV, HTLV and Syphilis
•Adequate renal function
•Adequate hepatic function
•Adequate cardiac function
•Adequate venous access for apheresis, and no other contraindications for leukapheresis
•Voluntary informed consent is given.

Exclusion Criteria

•Pregnant or lactating women.
•Uncontrolled active infection.
•History of hepatitis B or hepatitis C infection.
•Previously treatment with any gene therapy products or cell therapy product in past 28 days.
•Cannot undergo MRI with contrast or SPECT/CT
•HIV infection.
•Have autoimmune disorders
•Have active infection or inflammatory disorders
•Prescreening test results in expansion rate less than 5 folds
•An allergy to gentamycin and/or streptomycin

Key Dates

Start Date

September 1, 2021

Primary Completion Date

September 30, 2023

Completion Date

December 31, 2023

Last Updated

January 22, 2021

Enrollment

ESTIMATED participants

Conditions

Recurrent Glioblastoma

Interventions

NKG2D CAR-T

BIOLOGICAL

Contacts

Cheng-Yi Kuo, PhD

CONTACT

+886-2-26972200 jerry.kuo@uwell.com.tw

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITINGPHASE1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT06344130

AstrocytomaGlioma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 22, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM